Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Regeneron (REGN)
NASDAQ:REGN
Regeneron (REGN) Stock Price & Analysis
3,979 Followers
REGN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$684.81 - $1,016.00
Previous Close$1,002.95
Volume250.10K
Average Volume (3M)440.53K
Market Cap
$110.49B
Enterprise Value$102.35B
Total Cash (Recent Filing)$10.84B
Total Debt (Recent Filing)$2.70B
Price to Earnings (P/E)29.6
Beta0.68
Next Earnings
Aug 01, 2024EPS Estimate
$10.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)33.85
Shares Outstanding110,185,503
10 Day Avg. Volume415,734
30 Day Avg. Volume440,532
Standard Deviation0.08
R-Squared0.00605
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)4.42
Price to Sales (P/S)8.29
Price to Cash Flow (P/CF)25.30
P/FCF Ratio34.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.80
Enterprise Value/Gross Profit9.06
Enterprise Value/Ebitda21.81
Forecast
1Y Price Target
$1,063.53Price Target Upside6.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
Regeneron News
Bulls Say, Bears Say
Bulls Say
Drug ApprovalCHMP has adopted a positive opinion recommending Dupi's approval in COPD patients, signaling trust in its effectiveness.
Earnings And Sales GrowthEylea HD sales come in ahead of consensus, demonstrating a strong market uptake and potential for continued revenue growth.
Pipeline DevelopmentRegeneron's expansion into oncology with Libtayo outperforming expectations and other treatments advancing towards key data readouts presents promising prospects for the company's future.
Bears Say
Financial PerformanceFinancials missed overall with top-line revenue and non-GAAP EPS falling behind estimates.
Legal And Competitive RisksFDA approved two Eylea biosimilars with interchangeability designation, potentially infringing on REGN's '865 Eylea formulation patent.
Regulatory ChallengesFDA decides additional BOREAS and NOTUS data constitutes a major amendment to original application for approval of Dupixent in COPD, resulting in a delayed PDUFA for Dupixent.
---
Ownership Overview
2.93% Insiders
34.46% Mutual Funds
42.32% Other Institutional Investors
20.28% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
REGN FAQ
What was Regeneron’s price range in the past 12 months?
Regeneron lowest stock price was $684.80 and its highest was $1016.00 in the past 12 months.
What is Regeneron’s market cap?
Currently, no data Available
When is Regeneron’s upcoming earnings report date?
Regeneron’s upcoming earnings report date is Aug 01, 2024 which is in 53 days.
How were Regeneron’s earnings last quarter?
Regeneron released its earnings results on May 02, 2024. The company reported $9.55 earnings per share for the quarter, missing the consensus estimate of $10.171 by -$0.621.
Is Regeneron overvalued?
According to Wall Street analysts Regeneron’s price is currently Undervalued.
Does Regeneron pay dividends?
Regeneron does not currently pay dividends.
What is Regeneron’s EPS estimate?
Regeneron’s EPS estimate is $10.58.
How many shares outstanding does Regeneron have?
Regeneron has 108,367,355 shares outstanding.
What happened to Regeneron’s price movement after its last earnings report?
Regeneron reported an EPS of $9.55 in its last earnings report, missing expectations of $10.171. Following the earnings report the stock price went up 3.778%.
Which hedge fund is a major shareholder of Regeneron?
Among the largest hedge funds holding Regeneron’s share is Dodge & Cox. It holds Regeneron’s shares valued at 2B.
---
Regeneron Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1,063.53 (6.04% Upside)
$1,063.53 (6.04% Upside)
Blogger Sentiment
Bullish
REGN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 73.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▲ 6.7%
Last 30 Days ▲ 6.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.78%
12-Months-Change
Fundamentals
Return on Equity
15.28%
Trailing 12-Months
Asset Growth
14.34%
Trailing 12-Months
Company Description
Regeneron
Founded in 1988, Regeneron Pharmaceuticals, Inc. is a New York-based biotechnology company, which discovers, develops, manufactures, and commercializes medicines for the treatment of various medical conditions. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP.
---
REGN Company Deck
---
REGN Earnings Call
Q1 2024
0:00 / 0:00
---
REGN Revenue Breakdown
44.87% EYLEA - U.S.
28.97% Sanofi
11.34% Bayer
4.11% Libtayo - U.S.
10.72% Other
---
REGN Stock 12 Month Forecast
Average Price Target
$1,063.53
▲(6.04% Upside)
Technical Analysis
Best Analysts Covering REGN
1 Year
1 Year Success Rate
20/21 ratings generated profit
1 Year Average Return
+19.10%
reiterated a buy rating 9 days ago
Copying Mohit Bansal's trades and holding each position for 1 Year would result in 95.24% of your transactions generating a profit, with an average return of +19.10% per trade.
---